Research Radartracking 1,189 published studies · 293 human · 6 safety signals · 42 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →

Research Radar

New PubMed studies on repurposed drugs and natural compounds in cancer — summarized in plain language and reviewed by a person before posting.

How to read this page. These studies are automatically collected from PubMed and summarized by AI from the abstract, then reviewed by a human before publishing. Each summary describes only what that study reported — most are early lab, animal, or small human studies, and findings often conflict. This is educational information, not medical advice, and not a recommendation to take anything. Always talk with your oncologist.
Topic tags. Each study is filed under its main topic. Anticancer studies are the default; these tags flag the other dimensions:
Safety — Safety & interactionsAbsorption (PK) — How it's absorbed (PK)Formulation — Formulation & deliverySupportive care — Symptom & supportive careMetabolism — Metabolism & pathwaysTrial — Clinical trialMechanism — Biomarker & mechanism
Showing studies that mention “large-cell neuroendocrine carcinoma”.
1 of 200 studies
Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 216

Identification of Actionable Gene Variants in Pulmonary Large-Cell Neuroendocrine Carcinoma: A Real-World Analysis of a Polish Cohort

International journal of molecular sciences · Mar 2026 · retrospective cohort

pulmonary large-cell neuroendocrine carcinomaLCNEC

Researchers performed targeted next-generation sequencing on 216 pulmonary LCNEC tumor samples from a retrospective Polish cohort to look for actionable gene variants. They found 46 variants in 46/216 samples (21.3%), with 28/216 (13%) harboring at least one potentially actionable alteration; most common were KRAS and PIK3CA (each 5%), and a novel TMEM79::NTRK1 fusion was found in one case (0.5%). Several typical NSCLC alterations (classical EGFR exon 18–21, ALK, FGFR1/2/3, ROS1) were not detected.

Reported effects: variant_count 46, n=216 · variant_positive_rate 21.3%, n=216 · +8 more

Key findings
  • Overall, 46 variants were identified in 46/216 (21.3%) tumor samples.
  • 28/216 (13%) LCNECs harbored at least one actionable molecular variant potentially targetable by registered or investigational agents.
  • KRAS variants were present in 5% of tumors (including G12C at 2%).
  • PIK3CA variants were present in 5% of tumors.
  • RET single-nucleotide variants were observed in 3% of tumors.
  • Uncommon EGFR variants were observed in 1% of tumors; BRAF class II and III variants were observed at <1%.
  • A novel in-frame gene fusion (TMEM79::NTRK1) was identified in a single tumor sample (0.5%).
  • No classical EGFR exon 18-21 mutations nor ALK, FGFR1/2/3, or ROS1 alterations (mutations or fusions) were detected.
Limitations: Retrospective study design.; Targeted NGS panel limited to 17 genes, so alterations outside the panel would not be detected.; Single-country (Polish) cohort which may limit generalizability.; No clinical outcome or treatment-response data reported in the abstract to link variants to patient benefit..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text